## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($969.29)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Lilly shifts ambition for broader oral SERD label to largest oncology trial in company history**
- Source: Fierce Pharma | 20251213T150828 | Neutral | Relevance: 100%
- Eli Lilly will not seek a broad FDA approval for its oral SERD Inluriyo combined with Verzenio for breast cancer, instead focusing on a more limited label for patients with ESR1 gene mutations. Despite promising results for the combination in a wider patient group, the company acknowledges difficulties with FDA approval for an all-comers indication. Lilly is now directing its efforts towards the adjuvant setting with the Ember-4 trial, which will be its largest oncology trial, to test Inluriyo in a post-CDK4/6 environment.

**2. Eli Lilly (LLY) Stock Is Up, What You Need To Know**
- Source: Finviz | 20251211T170853 | Bullish | Relevance: 100%
- Eli Lilly's stock jumped after announcing highly positive Phase 3 trial results for its next-generation weight loss candidate, retatrutide. The drug achieved significant weight loss and improved physical function, surpassing the efficacy of their existing blockbuster, Zepbound. This success reinforces Lilly's strong position in the cardiometabolic health market.

**3. Lilly’s three-pronged drug puts obesity field ‘on notice’**
- Source: BioPharma Dive | 20251211T140820 | Bullish | Relevance: 100%
- Eli Lilly's experimental obesity drug, retatrutide, demonstrated significant weight loss and relief from knee osteoarthritis in a Phase 3 study, with patients on the highest dose losing an average of 28.7% of their body weight. This achievement sets a new benchmark in the obesity drug market, surpassing Lilly's own tirzepatide. The drug's mechanism involves activating three different receptors: GLP-1, GIP, and glucagon, showcasing its potential to reshape the competitive landscape for obesity treatments.

**4. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial | Eli Lilly and Company**
- Source: Eli Lilly and Company | 20251211T120833 | Bullish | Relevance: 100%
- Eli Lilly and Company announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial for retatrutide, a triple hormone receptor agonist, showing significant weight loss and improvements in knee osteoarthritis pain and physical function. Participants treated with retatrutide lost an average of up to 28.7% (71.2 lbs) of body weight and experienced up to a 75.8% reduction in WOMAC pain scores. These results highlight retatrutide's potential as an important option for patients with obesity and complications like knee osteoarthritis, with additional Phase 3 readouts expected in 2026.

**5. Drug giant Eli Lilly announces major manufacturing facility in Huntsville**
- Source: Alabama Daily News | 20251210T180808 | Bullish | Relevance: 100%
- Eli Lilly and Co. announced plans to build a new $6 billion manufacturing facility in Huntsville, Alabama, creating 450 new jobs. This will be the largest initial investment in Alabama's history and was secured through significant state incentives. The facility will produce small-molecule synthetic and peptide medicines, including forforglipron, Lilly's oral medication for diabetes and obesity.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 8, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |
| 2025-11-24 | Bernstein | $1300 | $1100 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |
| 2025-11-24 | Bernstein | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 15 ($2.06M) |
| Sells | 30 ($207.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $208M sold (30 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 8 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +8.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Forward P/E 31.7x attractive for 37% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (8 raises, avg +12%). Insider selling cluster ($208.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $921.1B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 31.7 |
| Current P/E | 43.4 |
| YoY Growth | 36.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -6.1% to 2.2% (+8.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.8pp (needs >3.0% for momentum thesis). MRS_5 at 3.9% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.26x) but short-term weakness (below SMA20). MACD histogram bearish (-12.88), momentum weakening. RSI neutral at 58. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.23% (CS: 55) | Neutral |
| RSI_14 | 57.8 | Neutral |
| MACD Histogram | -12.88 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.099x | Above |
| vs SMA200 | 1.261x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1027.51
- **Stop Loss:** $969.29 (5.7% risk)
- **Target:** $1085.73 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 17
- **Position Value:** $17,467.67
- **Portfolio %:** 17.47%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*